B7-H4 expression and increased death risk of cancer patients: A meta-analysis
Tóm tắt
The relationship between higher levels of B7-H4 expression and death risk of cancer patients remains to be clarified. In the current study, information from an ordinary scale and those from several outcome scales were combined to make a single estimate. PubMed databases were searched for survival studies on the hazard ratios (HR) of malignant tumors associated with higher B7-H4 expression from 1999 to 2010. The fixed effect model was used to estimate the combined HRs of six studies. Sensitivity analysis was performed to assess the stability. Publication bias was also estimated. Six studies that meet the inclusion criteria were identified; these studies reported the associations between the higher B7-H4 expression and death risk of cancer patients. A 42% increase in death risk was observed in patients with higher B7-H4 expression (HR = 1.42; 95% confidence interval: 1.16–1.72). Sensitivity analyses found the results robust. The analysis shows that higher levels of B7-H4 expression are associated with the death risk of patients suffering from various cancers. B7-H4 may be a negative regulatory molecule for antitumor immune responses and a molecular target for tumor immunotherapy.
Tài liệu tham khảo
Aunoble B, Sanches R, Didier E, et al. Major oncogenes and tumor suppressor genes involved in epithelial ovarian cancer (review). Int J Oncol 2000; 16: 567–576.
Nicosia SV, Bai W, Cheng JQ, et al. Oncogenic pathways implicated in ovarian epithelial cancer. Hematol Oncol Clin North Am 2003; 17: 927–943.
Sica GL, Choi IH, Zhu G, et al. B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity 2003; 18: 849–861.
Prasad DV, Richards S, Mai XM, et al. B7S1, a novel B7 family member that negatively regulates T cell activation. Immunity 2003; 18: 863–873.
Zang X, Loke P, Kim J, et al. B7x: a widely expressed B7 family member that inhibits T cell activation. Proc Natl Acad Sci U S A 2003; 100: 10388–10392.
Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 2008; 8: 467–477.
Kryczek I, Zou L, Rodriguez P, et al. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med 2006; 203: 871–881.
Kryczek I, Wei S, Zhu G, et al. Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res 2007; 67: 8900–8905.
Kryczek I, Wei S, Zou L, et al. Cutting edge: induction of B7-H4 on APCs through IL-10: novel suppressive mode for regulatory T cells. J Immunol 2006; 177: 40–44.
Anderson GL, McIntosh M, Wu L, et al. Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study. J Natl Cancer Inst 2010; 102: 26–38.
Jiang J, Zhu Y, Wu C, et al. Tumor expression of B7-H4 predicts poor survival of patients suffering from gastric cancer. Cancer Immunol Immunother 2010; 59: 1707–1714.
Krambeck AE, Thompson RH, Dong H, et al. B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Natl Acad Sci U S A 2006; 103: 10391–10396.
Oikonomopoulou K, Li L, Zheng Y, et al. Prediction of ovarian cancer prognosis and response to chemotherapy by a serum-based multiparametric biomarker panel. Br J Cancer 2008.
Simon I, Katsaros D, Rigault de la Longrais I, et al. B7-H4 is over-expressed in early-stage ovarian cancer and is independent of CA125 expression. Gynecol Oncol 2007; 106: 334–341.
DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177–188.
Choi IH, Zhu G, Sica GL, et al. Genomic organization and expression analysis of B7-H4, an immune inhibitory molecule of the B7 family. J Immunol 2003; 171: 4650–4654.
Salceda S, Tang T, Kmet M, et al. The immunomodulatory protein B7-H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation. Exp Cell Res 2005; 306: 128–141.
Sun Y, Wang Y, Zhao J, et al. B7-H3 and B7-H4 expression in non-small-cell lung cancer. Lung Cancer 2006; 53: 143–151.
Zang X, Thompson RH, Al-Ahmadie HA, et al. B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci U S A 2007; 104: 19458–19463.
Tringler B, Zhuo S, Pilkington G, et al. B7-h4 is highly expressed in ductal and lobular breast cancer. Clin Cancer Res 2005; 11: 1842–1848.
Sun Y, Liu J, Cui X, et al. Clinical significance of expression of B7-H4 in colon and rectal cancer tissues. Journal Of Shandong University (Health Sciences) 2006; 44: 590–592.
Awadallah NS, Shroyer KR, Langer DA, et al. Detection of B7-H4 and p53 in pancreatic cancer: potential role as a cytological diagnostic adjunct. Pancreas 2008; 36: 200–206.
Yao Y, Wang X, Jin K, et al. B7-H4 is preferentially expressed in non-dividing brain tumor cells and in a subset of brain tumor stem-like cells. J Neurooncol 2008; 89: 121–129.
Watanabe N, Gavrieli M, Sedy JR, et al. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol 2003; 4: 670–679.
Compaan DM, Gonzalez LC, Tom I, et al. Attenuating lymphocyte activity: the crystal structure of the BTLAHVEM complex. J Biol Chem 2005; 280: 39553–39561.
Gonzalez LC, Loyet KM, Calemine-Fenaux J, et al. A coreceptor interaction between the CD28 and TNF receptor family members B and T lymphocyte attenuator and herpesvirus entry mediator. Proc Natl Acad Sci U S A 2005; 102: 1116–1121.
Sedy JR, Gavrieli M, Potter KG, et al. B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator. Nat Immunol 2005; 6: 90–98.